Investigational drug · Phase 3
Telisotuzumab Adizutecan
Also called: ABBV-400
Not approved by FDA. In 16 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
16
16 still active
All registered trials
18
Any phase or sponsor naming "Telisotuzumab Adizutecan"
First trial start
2023
Nov 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- AbbVie14
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Telisotuzumab Adizutecan", any sponsor or status.
- Phase 213
Conditions studied
As listed on its trial records.
- c-MET
- Non-Squamous Non-Small Cell Lung Cancer
- Metastatic Colorectal Cancer
- Colorectal Cancer
- Solid Tumors Harboring MET Amplification
- Head and Neck Squamous Cell Carcinoma
- Unresectable Metastatic Colorectal Cancer
- Non Small Cell Lung Carcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- PDAC
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Telisotuzumab Adizutecan" as an intervention, largest first.
AbbVieAbbVie (ABBV)
NCT07525206 · 990 participants (planned) · Start May 22, 2026 · Primary completion May 2029
Drug: Telisotuzumab adizutecan; Bevacizumab and 1 more · For: Colorectal Cancer
Sites: Goodyear, Arizona; Springdale, Arkansas; Duarte, California · 91 sites in all
AbbVieAbbVie (ABBV)
NCT07490301 · 900 participants (planned) · Start Apr 30, 2026 · Primary completion Jun 2031
Drug: Telisotuzumab adizutecan; Fluorouracil and 3 more · For: Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
Sites: New Haven, Connecticut; Chicago, Illinois; Zion, Illinois · 22 sites in all
AbbVieAbbVie (ABBV)
NCT07005102 · 854 participants (planned) · Start Aug 3, 2025 · Primary completion Nov 2036
Drug: Standard of Care; Telisotuzumab Adizutecan and 4 more · For: Non-Squamous Non-Small Cell Lung Cancer; c-MET
Sites: Chandler, Arizona; Duarte, California; Irvine, California · 65 sites in all
AbbVieAbbVie (ABBV)
NCT05005403 · 694 participants (planned) · Start Nov 1, 2021 · Primary completion Jul 2027
Drug: Azirkitug; Budigalimab and 2 more · For: Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer and 4 more
Sites: Duarte, California; Irvine, California; Los Angeles, California · 48 sites in all
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
AbbVieAbbVie (ABBV)
NCT07821684 · 660 participants (planned) · Start Jan 6, 2027 · Primary completion Mar 2030
Drug: Telisotuzumab Adizutecan; Docetaxel and 1 more · For: Non-Squamous Non-Small Cell Lung Cancer
AbbVieAbbVie (ABBV)
NCT07155187 · 490 participants (planned) · Start Dec 10, 2025 · Primary completion Sep 2030
Drug: Telisotuzumab Adizutecan; Standard of Care and 1 more · For: Non-Small Cell Lung Cancer; c-MET
Sites: Springdale, Arkansas; Duarte, California; Irvine, California · 117 sites in all
- Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal CancerPivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07895355 · 412 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: RC148 plus Telisotuzumab adizutecan; RC148 plus Telisotuzumab adizutecan and 4 more · For: Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Sites: Guangdong, China
AbbVieAbbVie (ABBV)
NCT06820463 · 390 participants (planned) · Start Apr 24, 2025 · Primary completion Mar 2028
Drug: Telisotuzumab Adizutecan; Fluorouracil and 4 more · For: Metastatic Colorectal Cancer
Sites: Duarte, California; Santa Monica, California; New Haven, Connecticut · 82 sites in all
AbbVieAbbVie (ABBV)
NCT06772623 · 252 participants (planned) · Start Mar 6, 2025 · Primary completion Nov 2027
Drug: Telisotuzumab Adizutecan; Budigalimab and 5 more · For: Non Small Cell Lung Carcinoma; c-MET
Sites: Phoenix, Arizona; Fullerton, California; Oxnard, California · 131 sites in all
- Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung CancerPivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07874282 · 200 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: Telisotuzumab adizutecan plus RC148(ABBV-1480); Telisotuzumab adizutecan plus RC148(ABBV-1480) · For: Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.
Cecchini M, Cruz-Correa M, Han SW, et al. · Ann Oncol 2026
- Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models.
Subramanian S, High PC, Guernsey-Biddle C, et al. · bioRxiv 2026
- Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody-drug conjugate with a topoisomerase inhibitor payload.
Matsubara Y, Kawazoe A · Expert Opin Investig Drugs 2026
- Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
Sharma MR, Powderly J, Kuboki Y, et al. · J Clin Oncol 2026
- Has Colorectal Cancer (c-)Met Its Match With Telisotuzumab Adizutecan?
Brown TJ, Ozer M, Grewal US, et al. · J Clin Oncol 2026
- Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
Sharma MR, Powderly J, Kuboki Y, et al. · J Clin Oncol 2026
Also in development for c-MET
- BudigalimabABBV-181Phase 36 trials
AbbVie · Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.